^
Association details:
| Biomarker: | PD-L2 overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway
Excerpt:
The results indicate that HIF-1_H exhibited the highest expression of PD-L1, PD1, and PD-L2, while HIF-1_L had the lowest expression of PD-L1, PD1, and PD-L2 (Kruskal–Wallis test, P < 0.05) (Figures 4A,B). This suggests that PCa subtype HIF-1_H may have a better response to anti-PD-L1 immunotherapy...
DOI:
https://doi.org/10.3389/fonc.2020.01374
